Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ABBV-637 + ERAS-801 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ABBV-637 | ABBV637|ABBV 637 | EGFR Antibody 72 | ABBV-637 is an antibody-drug conjugate (ADC) comprising an antibody targeting EGFR linked to a BCL-XL inhibitor, which potentially induces antitumor activity (Ann Oncol (2023) 34 (suppl_2): S759). | |
| ERAS-801 | ERAS801|ERAS 801 | EGFR Inhibitor (Pan) 63 | ERAS-801 is an EGFR inhibitor with improved blood-brain barrier penetrating ability, potentially leading to inhibition of growth of EGFR-overexpressing tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06934889 | Phase I | ABBV-637 + ERAS-801 ABBV-637 + Temozolomide ERAS-801 + Mirzotamab clezutoclax Mirzotamab clezutoclax + Temozolomide | Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma | Recruiting | USA | 0 |